Poseida Therapeutics (NASDAQ:PSTX) Earns “Buy” Rating from HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $20.00 price target on the stock.

Poseida Therapeutics Price Performance

Shares of PSTX opened at $3.21 on Friday. Poseida Therapeutics has a one year low of $1.87 and a one year high of $4.27. The stock’s fifty day moving average is $2.81 and its 200-day moving average is $2.91. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The firm has a market capitalization of $312.85 million, a price-to-earnings ratio of -5.10 and a beta of 0.54.

Institutional Trading of Poseida Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Bayesian Capital Management LP acquired a new stake in Poseida Therapeutics in the first quarter worth approximately $33,000. Marshall Wace LLP acquired a new stake in shares of Poseida Therapeutics in the second quarter valued at $31,000. Rothschild Investment LLC acquired a new stake in shares of Poseida Therapeutics in the second quarter valued at $35,000. Principal Financial Group Inc. bought a new position in Poseida Therapeutics during the second quarter valued at about $35,000. Finally, Intech Investment Management LLC acquired a new position in Poseida Therapeutics during the third quarter worth about $46,000. 46.87% of the stock is owned by institutional investors and hedge funds.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.